The latest update is out from Perrigo Company (PRGO).
Perrigo Company plc successfully sold its HRA Pharma Rare Diseases business to Esteve Healthcare, S.L. for up to €275 million, after exercising a put option agreement. This deal, finalized on July 10, 2024, includes €190 million in cash and the potential for €85 million more based on future sales milestones. The companies have made several commitments, including operational covenants and employee non-solicitation, until the sale’s completion. While detailed terms are outlined in the Purchase Agreement, investors should note these are for contractual purposes and are not necessarily reflective of the current state or material to investment decisions.
Learn more about PRGO stock on TipRanks’ Stock Analysis page.
